{
    "fund_name": "Invesco NASDAQ Biotech UCITS ETF",
    "type": "ETF",
    "ucits": true,
    "leverage": false,
    "derivatives": true,
    "swaps": true,
    "inverse": false,
    "replication_method": "synthetic",
    "complex_factors": [
        "Swaps",
        "Synthetic Replication",
        "Counterparty Risk"
    ],
    "classification": "complex",
    "supporting_data": "The ETF uses unfunded swaps to achieve its investment objective, which introduces counterparty risk and reliance on derivative agreements. The KIID explicitly mentions 'Synthetic ETF Risk' and highlights the dependency on counterparties to deliver the benchmark performance. The risk category is 6, indicating higher risk, and the use of derivatives for index tracking is a key complexity indicator under MiFID II. The fund's synthetic replication method and the associated risks, such as potential tracking errors and counterparty insolvency, contribute to its classification as complex.",
    "confidence": 90,
    "counter_argument": "The ETF is UCITS-compliant and has a straightforward objective of tracking the NASDAQ Biotechnology Index. However, the use of swaps and synthetic replication overrides this simplicity, as these features introduce additional layers of risk and complexity that may not be easily understood by retail investors.",
    "risk_level": 6,
    "additional_notes": "The PRIIPs KID and factsheet reinforce the synthetic nature of the ETF and the reliance on swap agreements, which are clear indicators of complexity under MiFID II. The absence of leverage or inverse strategies does not mitigate the complexity introduced by the derivative usage and counterparty risk."
}